Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | The need for biomarkers to begin clinical trials for ataxia treatment

Henry Paulson, MD, PhD, University of Michigan, Ann Arbor, MI, discusses the need for biomarkers to measure the severity of ataxia. The current clinical scales are inherently low resolution and are not sophisticated enough to form clinical trials for potential treatment. With biomarkers, better imaging and better biomolecule detection, clinical trials can commence to find a treatment for these fatal diseases. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).